CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CANDOR STUDY BY NUMBER OF PRIOR LINES OFTHERAPY AND PRIOR THERAPIES H. Quach, A. Nooka, O. Samoylova, C.P. Venner, T. Facon, A. Spencer, S.Z. Usmani, K. Weisel, M. Mateos, K. Kim, S. Grosicki, K. Suzuki, S. Delimpasi, M. Obreja, A. Zahlten-Kumeli

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY A. Maiolino, P. Moreau, M. Dimopoulos, J. Mikhael, K. Yong, M. Capra, T. Facon, R. Hajek, I. Spicka, M. Risse, G. Asset, S. Macé, T. Martin

Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-label study M. Turgut, P. Moreau, M. Dimopoulos, J. Mikhael, K. Yong, M. Capra, T. Facon, R. Hajek, I. Spicka, M. Risse, G. Asset, S. Macé, T. Martin